Komorbidität affektiver Erkrankungen und alkoholbezogener Störungen

Zusammenfassung

Psychische Erkrankungen und Alkoholkonsumstörungen sind häufig komorbid. Die aktuell gültigen S3-Leitlinien zu alkoholbezogenen Störungen fassen die Studienlage bis 2012 zusammen und entwickelt evidenzbasiert abgeleitete Empfehlungen für die klinische Praxis. Ziel dieses Beitrages ist es, die Ergebnisse der S3-Leitlinienentwicklung zur Komorbidität mit affektiven Erkrankungen und alkoholbezogenen Störungen zusammen zu fassen und aktuelle Studien aus den Folgejahren zu berücksichtigen. Die Entwicklungen in Epidemiologie, Psycho- und Pharmakotherapie sowie der Einsatz von digitalen oder internetbasierten Verfahren wird dargestellt.

Summary

Alcohol-related disorders have a high comorbidity with mental disorders. In currently available S3 guidelines on alcohol use disorders include RCT and studies between the years 2005 and 2012. Evidence-based recommendations were developed for clinical practice. The aim of this paper is to update the S3 guideline studies and to include recent research during the last years. This recent current research includes results from epidemiological, psychotherapy and psychopharmacological studies. Studies on digital and internet-based approaches are presented too.

Schlüsselwörter

Alkoholkonsumstörungen - Komorbidität - psychische Erkrankungen

Keywords

Alcohol use disorders - comorbidity - mental disorders

• Literatur

• 1 Hoch E, Batra A, Mann K. Das S3-Leitlinienprogramm für substanzbezogener Störungen. Sucht 2012; 2: 14-25.
• 2 Regier DA, Farmer ME, Rae DS. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518.
• 3 Preuss UW, Gouzoulis-Mayfrank E, Havemann-Reinecke U, Schäfer I, Beutel M, Mann KF, Hoch E. Mental comorbidities of alcohol-related disorders. Nervenarzt 2016; 87 (01) 26-34.
• 4 Raimo EB, Schuckit MA. Alcohol dependence and mood disorders. Addict Behav 1998; 23 (06) 933-946.
• 5 Bega S, Schaffer A, Goldstein B, Levitt A. Differentiating between Bipolar Disorder types I and II: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Affect Disord 2012; 138 (1-2): 46-53.
• 6 Preuss UW. Abhängigkeitserkrankungen und Psychosen: Erkenntnisse und Kontroversen in Vorbereitung auf neue Klassifikationssysteme. Die Psychiatrie 2008; 2: 61-68.
• 7 Preuss UW, Wong WMJ, Wurst FM. Bipolar affektive Störungen und Alkoholkonsum-störungen: Komorbidität, Konsequenzen und Therapie. Spektrum Psychiatrie 2012; 2: 47-51.
• 8 Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2007; 2: 29.
• 9 National Institute for Health and Clinical Excellence (NICE). Alcohol-use disorders: Diagnosis, assessment and management of harmful drinking and alcohol dependence (CG115). London: 2011
• 10 Haber P, Lintzeris N, Proude E. et al. Guidelines for the treatment of alcohol problems. Commonwealth of Australia; 2009
• 11 Iovieno N, Tedeschini E, Bentley KH. et al. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2011; 72 (08) 1144-1151.
• 12 Pettinati HM, Oslin DW, Kampman KM. et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010; 167 (06) 668-675.
• 13 Mann KF, Hoch E, Batra A. AWMF-S3-Leitlinie „Screening, Diagnose und Behandlung alkoholbezogener Störungen“. Heidelberg: Springer; 2016
• 14 Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62 (01) 37-45.
• 15 Weiss RD. et al. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 2007; 164: 100-107.
• 16 Farren CK, Snee L, McElroy S. Gender differences in outcome at 2-year follow-up of treated bipolar and depressed alcoholics. J Stud Alcohol Drugs 2011; 72 (05) 872-880.
• 17 Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord 2012; 14 (01) 54-63
• 18 Brown ES, Beard L, Dobbs L, Rush AJ. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety 2006; 23 (08) 492-495.
• 19 Bolton JM, Robinson J, Sareen J. Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions. J Affect Disord 2009; 115 (03) 367-75.
• 20 Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry 2008; 69 (05) 701-705.
• 21 Petrakis IL, Leslie D, Finney JW, Rosenheck R. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 2006; 15 (01) 44-49.
• 22 Sherwood-Brown E. et al. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res 2014; 38 (07) 2113-8.
• 23 Sylvia LG. et al. A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder. Am J Addict 2016; 25 (02) 94-8.
• 24 Sylvia LG. et al. A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder. Am J Addict 2016; 25 (02) 94-8.
• 25 Witte J. et al. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. J Clin Psychopharmacol 2012; 32 (06) 787-96.
• 26 Cornelius JR. et al. Mirtazapine in comorbid major depression and alcohol use disorder: a long-term follow-up study. J Addict Behav Ther Rehabil 2013; 3 (01) 1560.
• 27 Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. Am J Addict 2014; 23 (03) 288-93.
• 28 Baker AL, Kay-Lambkin FJ, Gilligan C, Kavanagh DJ, Baker F, Lewin TJ. When does change begin following screening and brief intervention among depressed problem drinkers?. J Subst Abuse Treat 2013; 44 (03) 264-70.
• 29 Baker AL, Kavanagh DJ, Kay-Lambkin FJ, Hunt SA, Lewin TJ, Carr VJ, McElduff P. Randomized controlled trial of MICBT for co-existing alcohol misuse and depression: outcomes to 36-months. J Subst Abuse Treat 2014; 46 (03) 281-90.
• 30 Worley MJ, Trim RS, Tate SR, Roesch SC, Myers MG, Brown SA. Self-efficacy and social networks after treatment for alcohol or drug dependence and major depression: disentangling person and time-level effects. Psychol Addict Behav 2014; 28 (04) 1220-9.
• 31 Satre DD, Delucchi K, Lichtmacher J, Sterling SA, Weisner C. Motivational interviewing to reduce hazardous drinking and drug use among depression patients. J Subst Abuse Treat 2013; 44 (03) 323-9.
• 32 Riper H, Andersson G, Hunter SB, de Wit J, Berking M, Cuijpers P. Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis. Addiction 2014; 109 (03) 394-406.
• 33 Kalapatapu RK, Ho J, Cai X, Vinogradov S, Batki SL, Mohr DC. Cognitive-behavioral therapy in depressed primary care patients with co-occurring problematic alcohol use: effect of telephone-administered vs. face-to-face treatment-a secondary analysis. J Psychoactive Drugs 2014; 46 (02) 85-92.
• 34 Agyapong VI, Ahern S, McLoughlin DM, Farren CK. Supportive text messaging for depression and comorbid alcohol use disorder: single-blind randomised trial. J Affect Disord 2012; 141 (2-3): 168-76.
• 35 Agyapong VI, McLoughlin DM, Farren CK. Six-months outcomes of a randomised trial of supportive text messaging for depression and comorbid alcohol use disorder. J Affect Disord 2013; 151 (01) 100-4.
• 36 Pettinati HM, O‘Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry 2013; 170 (01) 23-30.
• 37 Charney DA, Heath LM, Zikos E, Palacios-Boix J, Gill KJ. Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2015; 39 (09) 1756-65.
• 38 Foulds JA, Douglas Sellman J, Adamson SJ, Boden JM, Mulder RT, Joyce PR. Depression outcome in alcohol dependent patients: an evaluation of the role of independent and substance-induced depression and other predictors. J Affect Disord 2015; 174: 503-10.